Techstarsan organization that invests in early-stage startups, Johns Hopkins and CareFirst BlueCross BlueShield, introduced the launch of a brand new healthcare accelerator program designed to help early-stage entrepreneurs utilizing synthetic intelligence to enhance care pathways.
With the backing of Johns Hopkins and CareFirst, Techstars AI Well being Baltimore makes use of the college’s proficiency in changing analysis into commercially possible companies.
It additionally takes benefit of CareFirst’s expertise in advancing entry to economical, honest, high-quality healthcare and Techstars’ accelerator mannequin.
The Baltimore-based accelerator program goals to construct on the success of Techstars Equitech, which is a three-cohort sequence at the side of UpSurge Baltimore that led to Could.
Baltimore’s expertise ecosystem builder, UpSurge will proceed to make sure that Techstars founders can leverage the extensive continuum of belongings that exist within the larger Baltimore space.
Adam Phillips, former managing director of Techstars Equitech, will spearhead the 13-week program targeted on supporting entrepreneurs main healthtech, medtech and biotech startups.
Startups will get capital, steering from consultants and different help wanted to navigate the complexities of the healthcare ecosystem and regulatory atmosphere.
Purposes open on Aug. 26 and will probably be accepted by way of Nov. 20.
Myra Norton, head of startup acceleration at Johns Hopkins Expertise Ventures, the college’s commercialization and entrepreneurship arm, mentioned that “by collaborating with Techstars on the intersection of healthcare and AI, Johns Hopkins goals to carry extra entrepreneurs to our ecosystem and catalyze extra startup exercise to carry high-impact healthcare innovation to market.”
THE LARGER TREND
In 2021, Techstars was among the many traders in UAEs Klaim, a healthtech startup that raised $1.6 million (€1.4 million) in funding in a pre-Sequence A spherical. The funding enabled Klaim’s penetration within the Saudi and U.S. markets.
On Aug. 15, Johns Hopkins Kimmel Most cancers Heart investigators revealed a novel take a look at could present gastroenterologists with perception into which sufferers with Barrett’s esophagus are prone to progress to esophageal most cancers or an irregular assortment of cells referred to as high-grade dysplasia. The data may assist physicians decide monitor or handle sufferers throughout medical care.
In July, Johns Hopkins Expertise Ventures introduced the improvement of particular nanoparticles that may ship gene therapy straight to varied kinds of cells in bone marrow to appropriate the disease-causing mutations.
That very same month, utilizing genetic engineering methods, investigators on the Johns Hopkins Kimmel Most cancers Heart and its Ludwig Heart, the Lustgarten Laboratory and Bloomberg~Kimmel Institute for Most cancers Immunotherapy designed a novel kind of cell to acknowledge and battle most cancers.
Different firms providing healthcare accelerator packages embrace Duke-NUS Medical College, which launched a $20 million incubator, LIVE Ventures, in July, to assist commercialize educational analysis initiatives and rework scientific breakthroughs into medical purposes.
The incubator goals to produce educational innovators with experience and sources from the private and non-private sectors – together with pharmaceutical firms, market knowledge analysis professionals, traders and business consultants – to conduct product-market match evaluations for undertaking commercialization.
Mayo Clinic’s Platform_Accelerate is a 30-week program that helps early-stage well being tech AI startups get market prepared.
Penn Well being-Tech’s Well being-Tech Accelerator is a yearlong, cohort-based program that’s meant to offer help by way of advising and funding geared toward accelerating the life cycle of progressive well being applied sciences.
The HIMSS AI in Healthcare Discussion board is scheduled to happen Sept. 5-6 in Boston. Study extra and register.
